Advertisement

Topics

Aeterna Zentaris Resubmits NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults

09:15 EDT 30 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”) today announced that it has resubmitted a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of Macrilen™ ...

Other Sources for this Article

Aeterna Zentaris Inc.
Philip A. Theodore, 843-900-3211
Senior Vice President
ir@aezsinc.com

NEXT ARTICLE

More From BioPortfolio on "Aeterna Zentaris Resubmits NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...